Daniel Paris

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11815789/publications.pdf

Version: 2024-02-01

74 papers	3,497 citations	126907 33 h-index	144013 57 g-index
76 all docs	76 docs citations	76 times ranked	4763 citing authors

#	Article	IF	Citations
1	Characterization of immune profile in an aging multiple sclerosis clinic population. Multiple Sclerosis and Related Disorders, 2022, 63, 103818.	2.0	1
2	Mural cell dysfunction leads to altered cerebrovascular tau uptake following repetitive head trauma. Neurobiology of Disease, 2021, 150, 105237.	4.4	12
3	A 3-month-delayed treatment with anatabine improves chronic outcomes in two different models of repetitive mild traumatic brain injury in hTau mice. Scientific Reports, 2021, 11, 7900.	3.3	6
4	Novel, natural allosteric inhibitors and enhancers of Candida rugosa lipase activity. Bioorganic Chemistry, 2021, 109, 104732.	4.1	3
5	MMP9 modulation improves specific neurobehavioral deficits in a mouse model of Alzheimerâ€™s disease. BMC Neuroscience, 2021, 22, 39.	1.9	25
6	Nilvadipine suppresses inflammation via inhibition of P-SYK and restores spatial memory deficits in a mouse model of repetitive mild TBI. Acta Neuropathologica Communications, 2020, 8, 166.	5.2	11
7	The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial. Frontiers in Neurology, 2020, 11, 149.	2.4	14
8	Apolipoprotein E isoforms differentially regulate matrix metallopeptidase 9 function in Alzheimerâ€™s disease. Neurobiology of Aging, 2020, 95, 56-68.	3.1	13
9	Neuronal Spleen tyrosine kinase (SYK) mediates cytokine release in Transgenic Tau P301S mice organotypic brain slice cultures. Neuroscience Letters, 2020, 729, 134992.	2.1	2
10	Targeting sirtuin activity with nicotinamide riboside reduces neuroinflammation in a GWI mouse model. NeuroToxicology, 2020, 79, 84-94.	3.0	23
11	Spleen tyrosine kinase (SYK) blocks autophagic Tau degradation in vitro and in vivo. Journal of Biological Chemistry, 2019, 294, 13378-13395.	3.4	31
12	A permethrin metabolite is associated with adaptive immune responses in Gulf War Illness. Brain, Behavior, and Immunity, 2019, 81, 545-559.	4.1	31
13	Distinct Signaling Pathways Regulate TREM2 Phagocytic and NFÎºB Antagonistic Activities. Frontiers in Cellular Neuroscience, 2019, 13, 457.	3.7	61
14	A fast, miniaturised in-vitro assay developed for quantification of lipase enzyme activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 1474-1480.	5.2	5
15	Blood Pressure Lowering With Nilvadipine in Patients With Mildâ€toâ€Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension. Journal of the American Heart Association, 2019, 8, e011938.	3.7	10
16	Î±-Sheet secondary structure in amyloid Î²-peptide drives aggregation and toxicity in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8895-8900.	7.1	118
17	Lifelong behavioral and neuropathological consequences of repetitive mild traumatic brain injury. Annals of Clinical and Translational Neurology, 2018, 5, 64-80.	3.7	110
18	Treatment With Nilvadipine Mitigates Inflammatory Pathology and Improves Spatial Memory in Aged hTau Mice After Repetitive Mild TBI. Frontiers in Aging Neuroscience, 2018, 10, 292.	3.4	14

#	Article	IF	Citations
19	Oleoylethanolamide treatment reduces neurobehavioral deficits and brain pathology in a mouse model of Gulf War Illness. Scientific Reports, 2018, 8, 12921.	3.3	36
20	Acute or Delayed Treatment with Anatabine Improves Spatial Memory and Reduces Pathological Sequelae at Late Time-Points after Repetitive Mild Traumatic Brain Injury. Journal of Neurotrauma, 2017, 34, 1676-1691.	3.4	29
21	Alzheimerâ€™s disease pathological lesions activate the spleen tyrosine kinase. Acta Neuropathologica Communications, 2017, 5, 69.	5.2	36
22	Chronic cerebrovascular abnormalities in a mouse model of repetitive mild traumatic brain injury. Brain Injury, 2016, 30, 1414-1427.	1.2	22
23	Chronic Anatabine Treatment Reduces Alzheimerâ€™s Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD. PLoS ONE, 2015, 10, e0128224.	2.5	26
24	Apolipoprotein E Isoform-Specific Effects on Lipoprotein Receptor Processing. NeuroMolecular Medicine, 2014, 16, 686-696.	3.4	41
25	The Spleen Tyrosine Kinase (Syk) Regulates Alzheimer Amyloid-Î² Production and Tau Hyperphosphorylation. Journal of Biological Chemistry, 2014, 289, 33927-33944.	3.4	84
26	Anatabine Attenuates Tau Phosphorylation and Oligomerization in P301S Tau Transgenic Mice. Brain Disorders & Therapy, 2014, 03, .	0.1	4
27	Role of the cannabinoid system in the transit of beta-amyloid across the bloodâ€“brain barrier. Molecular and Cellular Neurosciences, 2013, 56, 255-262.	2.2	39
28	Stimulation of the Retinoid X Receptor Facilitates Beta-Amyloid Clearance Across the Bloodâ€“Brain Barrier. Journal of Molecular Neuroscience, 2013, 49, 270-276.	2.3	38
29	A Multifaceted Role for apoE in the Clearance of Beta-Amyloid across the Blood-Brain Barrier. Neurodegenerative Diseases, 2013, 11, 13-21.	1.4	42
30	Anti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylation. European Journal of Pharmacology, 2013, 698, 145-153.	3.5	45
31	Amelioration of Experimental Autoimmune Encephalomyelitis by Anatabine. PLoS ONE, 2013, 8, e55392.	2.5	36
32	Selective Antihypertensive Dihydropyridines Lower AÎ² Accumulation by Targeting both the Production and the Clearance of AÎ² across the Blood-Brain Barrier. Molecular Medicine, 2011, 17, 149-162.	4.4	104
33	Epitope-Dependent Effects of Beta-Amyloid Antibodies on Beta-Amyloid Clearance in an In Vitro Model of the Blood-Brain Barrier. Microcirculation, 2011, 18, 373-379.	1.8	9
34	Selective dihydropyiridine compounds facilitate the clearance of Î²-amyloid across the bloodâ€“brain barrier. European Journal of Pharmacology, 2011, 659, 124-129.	3.5	61
35	Anatabine lowers Alzheimer's AÎ² production in vitro and in vivo. European Journal of Pharmacology, 2011, 670, 384-391.	3.5	51
36	Flavonoids lower Alzheimer's AÃŸ production via an NFkB dependent mechanism. Bioinformation, 2011, 6, 229-236.	0.5	39

#	Article	IF	Citations
37	Characterization and use of human brain microvascular endothelial cells to examine Î²-amyloid exchange in the blood-brain barrier. Cytotechnology, 2010, 62, 519-529.	1.6	30
38	Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimerâ€™s AÎ² Peptide. International Journal of Peptide Research and Therapeutics, 2010, 16, 23-30.	1.9	5
39	Alzheimerâ€™s Î²â€amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFRâ€2. Journal of Neurochemistry, 2010, 112, 66-76.	3.9	84
40	Impaired Orthotopic Glioma Growth and Vascularization in Transgenic Mouse Models of Alzheimer's Disease. Journal of Neuroscience, 2010, 30, 11251-11258.	3.6	25
41	Reduction of Î²-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. Journal of Neuroinflammation, 2010, 7, 17.	7.2	148
42	A 3D-QSAR model based screen for dihydropyridine-like compound library to identify inhibitors of amyloid beta (AÎ²) production. Bioinformation, 2010, 5, 122-127.	0.5	6
43	High Serum AÎ² and Vascular Risk Factors in First-Degree Relatives of Alzheimerâ€™s Disease Patients. Molecular Medicine, 2009, 15, 95-100.	4.4	16
44	Serum AÎ² Levels as Predictors of Conversion to Mild Cognitive Impairment/Alzheimer Disease in an ADAPT Subcohort. Molecular Medicine, 2009, 15, 432-437.	4.4	19
45	Serum Î²-Amyloid Correlates with Neuropsychological Impairment. Aging, Neuropsychology, and Cognition, 2009, 16, 203-218.	1.3	17
46	The granulocyte macrophage colony stimulating factor (GM-CSF) regulates amyloid Î² (AÎ²) production. Cytokine, 2008, 42, 336-344.	3.2	16
47	Diagnostic utility of APOE, soluble CD40, CD40L, and AÎ²1â€“40 levels in plasma in Alzheimerâ€™s disease. Cytokine, 2008, 44, 283-287.	3.2	37
48	Potent anti-angiogenic motifs within the Alzheimer Î²-amyloid peptide. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2008, 15, 5-19.	3.0	15
49	Inhibition of AÎ² production by NF-ÎºB inhibitors. Neuroscience Letters, 2007, 415, 11-16.	2.1	79
50	The influence of diagnosis, intra- and inter-person variability on serum and plasma AÎ² levels. Neuroscience Letters, 2007, 428, 53-58.	2.1	34
51	CD40 promotion of amyloid beta production occurs via the NF-ÎºB pathway. European Journal of Neuroscience, 2007, 25, 1685-1695.	2.6	19
52	Inhibition of angiogenesis and tumor growth by Î² and Î³-secretase inhibitors. European Journal of Pharmacology, 2005, 514, 1-15.	3.5	86
53	Anti-angiogenic activity of the mutant Dutch AÎ² peptide on human brain microvascular endothelial cells. Molecular Brain Research, 2005, 136, 212-230.	2.3	31
54	Genomic regulation after CD40 stimulation in microglia: Relevance to Alzheimer's disease. Molecular Brain Research, 2005, 140, 73-85.	2.3	30

#	Article	IF	Citations
55	Model of Alzheimerâ€™s disease amyloid-Î² peptide based on a RNA binding protein. Biochemical and Biophysical Research Communications, 2005, 332, 585-592.	2.1	17
56	Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. Journal of Neuroinflammation, 2005, 2, 9.	7.2	262
57	Nilvadipine antagonizes both AÎ² vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Research, 2004, 999, 53-61.	2.2	77
58	Inhibition of Angiogenesis by AÂ Peptides. Angiogenesis, 2004, 7, 75-85.	7.2	119
59	Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neuroscience Letters, 2004, 366, 80-85.	2.1	121
60	Increased TNFÎ± production and Cox-2 activity in organotypic brain slice cultures from APPsw transgenic mice. Neuroscience Letters, 2003, 353, 66-68.	2.1	22
61	Vasoactive effects of AÎ²in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: Role of inflammation. Neurological Research, 2003, 25, 642-651.	1.3	112
62	Statins inhibit AÎ²-neurotoxicity in vitro and AÎ²-induced vasoconstriction and inflammation in rat aortae. Atherosclerosis, 2002, 161, 293-299.	0.8	32
63	Pro-inflammatory effect of freshly solubilized Î²-amyloid peptides in the brain. Prostaglandins and Other Lipid Mediators, 2002, 70, 1-12.	1.9	41
64	Abeta Vasoactivity: An Inflammatory Reaction. Annals of the New York Academy of Sciences, 2000, 903, 97-109.	3.8	29
65	beta-Amyloid Vasoactivity and Proinflammation in Microglia Can Be Blocked by cGMP-Elevating Agents. Annals of the New York Academy of Sciences, 2000, 903, 446-450.	3.8	24
66	Cholesterol Modulates Vascular Reactivity to Endothelin-1 by Stimulating a Pro-inflammatory Pathway. Biochemical and Biophysical Research Communications, 2000, 274, 553-558.	2.1	22
67	Novel strategies for opposing murine microglial activation. Neuroscience Letters, 2000, 278, 5-8.	2.1	41
68	Soluble Î²-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway. Neurobiology of Aging, 2000, 21, 183-197.	3.1	61
69	Activation of microglial cells by the CD40 pathway: relevance to multiple sclerosis. Journal of Neuroimmunology, 1999, 97, 77-85.	2.3	73
70	Alzheimers disease is not associated with the hypertension genetic risk factors PLA2 or G protein ?3, either independently or interactively with apolipoprotein e. American Journal of Medical Genetics Part A, 1999, 88, 465-468.	2.4	4
71	Microglial Activation Resulting from CD40-CD40L Interaction After -Amyloid Stimulation. Science, 1999, 286, 2352-2355.	12.6	340
72	Inhibition of Alzheimer's Î²-Amyloid Induced Vasoactivity and Proinflammatory Response in Microglia by a cGMP-Dependent Mechanism. Experimental Neurology, 1999, 157, 211-221.	4.1	68

#	Article	IF	Citations
73	Isoform-specific vasoconstriction induced by Apolipoprotein E and modulation of this effect by Alzheimer's Î²-amyloid peptide. Neuroscience Letters, 1998, 256, 73-76.	2.1	39
74	Role of Peroxynitrite in the Vasoactive and Cytotoxic Effects of Alzheimer's Î²-Amyloid1â€“40Peptide. Experimental Neurology, 1998, 152, 116-122.	4.1	33